Skip to content
COMPANY
OVERVIEW
LEADERSHIP
BOARD
TIMELINE
OUR NETWORK
FOUNDERS
CONSULTANTS
INVESTORS
OUR SCIENCE
INTRODUCTION
Mode of Action
SCIENCE LIBRARY
PIPELINE
OVERVIEW
PMD-OPTION study
OMT-28
NEWS & EVENTS
TEAM & CAREERS
LEGAL NOTICE
DISCLAIMER
DATA PROTECTION
Back to NEWS
J.P. Morgan Healthcare Week 2026
Meet us in San Francisco, USA, January 12–15
https://bpjw.bio.org
Post navigation
OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases
OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study
